Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2\ue2\u88\u92) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
- Cicchiello, F.
- Riva, F.
- Cazzaniga, M. E.
- Pedani, F.
- Nicolini, M.
- Butti, C.
- Liscia, N.
- Pogliani, C.
- Capri, G.
- Al\uf9, M.
- Febbraro, A.
- Petrucelli, L.
- D'Onofrio, L.
- De Laurentiis, M.
- Pellegrini, D.
- Mentuccia, L.
- Cocciolone, V.
- Miraglio, E.
- Bajardi, E.
- Dester, M.
- Patern\uf2, E.
- Guaitoli, G.
- Ferrarini, I.
- Gervasi, E.
- Licata, L.
- Benedetto, C.
- Andreis, D.
- Bordin, E.
- Ancona, C.
- Pizzuti, L.
- Fotia, V.
- Berardi, R.
- Cazzaniga, M. E.
- Airoldi, M.
- Arcangeli, V.
- Artale, S.
- Atzori, F.
- Ballerio, A.
- Bianchi, G. V.
- Blasi, L.
- Campidoglio, S.
- Ciccarese, M.
- Cursano, M. C.
- Piezzo, M.
- Fabi, A.
- Ferrari, L.
- Ferzi, A.
- Ficorella, C.
- Frassoldati, A.
- Fumagalli, A.
- Garrone, O.
- Gebbia, V.
- Generali, D.
- La Verde, N.
- Maur, M.
- Michelotti, A.
- Moretti, G.
- Musolino, A.
- Palumbo, R.
- Pistelli, M.
- Porpiglia, M.
- Sartori, D.
- Scavelli, C.
- Schirone, A.
- Turletti, A.
- Valerio, M. R.
- Vici, P.
- Zambelli, A.
- Clivio, L.
- Torri, V.
DOIAbstract
BACKGROUND: The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. PATIENTS AND METHODS: This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. RESULTS: From July 2013 to December 2015, the EVA study enrol...
Add to ORKG